Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I, Non-Randomized, Feasibility Study for the Use of Bone Marrow Cell Concentrate Prepared Using the Magellan System for the Treatment of Critical Limb Ischemia

NCT01386216 is registered in ClinicalTrials.gov with Arteriocyte, Inc. as lead sponsor.

NCT NCT01386216
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01386216 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I, Non-Randomized, Feasibility Study for the Use of Bone Marrow Cell Concentrate Prepared Using the Magellan System for the Treatment of Critical Limb Ischemia
Lead sponsor
Arteriocyte, Inc.
Phase
Phase 1
Overall status
Completed
Start date
April 30, 2011
Completion date
December 31, 2016
Enrollment
18 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

critical limb ischemia (cli), peripheral vascular disease (pvd)